CN110511960B - 抗人乳头瘤病毒16 e6 t细胞受体 - Google Patents

抗人乳头瘤病毒16 e6 t细胞受体 Download PDF

Info

Publication number
CN110511960B
CN110511960B CN201910649441.7A CN201910649441A CN110511960B CN 110511960 B CN110511960 B CN 110511960B CN 201910649441 A CN201910649441 A CN 201910649441A CN 110511960 B CN110511960 B CN 110511960B
Authority
CN
China
Prior art keywords
seq
tcr
amino acid
cells
hpv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910649441.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN110511960A (zh
Inventor
克里斯蒂安·S·欣里西斯
史蒂文·A·罗森伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Health and Human Services filed Critical United States Department of Health and Human Services
Priority to CN201910649441.7A priority Critical patent/CN110511960B/zh
Publication of CN110511960A publication Critical patent/CN110511960A/zh
Application granted granted Critical
Publication of CN110511960B publication Critical patent/CN110511960B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN201910649441.7A 2013-07-15 2014-07-14 抗人乳头瘤病毒16 e6 t细胞受体 Active CN110511960B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910649441.7A CN110511960B (zh) 2013-07-15 2014-07-14 抗人乳头瘤病毒16 e6 t细胞受体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361846167P 2013-07-15 2013-07-15
US61/846,167 2013-07-15
CN201910649441.7A CN110511960B (zh) 2013-07-15 2014-07-14 抗人乳头瘤病毒16 e6 t细胞受体
PCT/US2014/046480 WO2015009606A1 (en) 2013-07-15 2014-07-14 Anti-human papillomavirus 16 e6 t cell receptors
CN201480044286.1A CN105452288B (zh) 2013-07-15 2014-07-14 抗人乳头瘤病毒16 e6 t细胞受体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480044286.1A Division CN105452288B (zh) 2013-07-15 2014-07-14 抗人乳头瘤病毒16 e6 t细胞受体

Publications (2)

Publication Number Publication Date
CN110511960A CN110511960A (zh) 2019-11-29
CN110511960B true CN110511960B (zh) 2023-05-23

Family

ID=51298958

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910649441.7A Active CN110511960B (zh) 2013-07-15 2014-07-14 抗人乳头瘤病毒16 e6 t细胞受体
CN201480044286.1A Active CN105452288B (zh) 2013-07-15 2014-07-14 抗人乳头瘤病毒16 e6 t细胞受体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480044286.1A Active CN105452288B (zh) 2013-07-15 2014-07-14 抗人乳头瘤病毒16 e6 t细胞受体

Country Status (8)

Country Link
US (5) US9822162B2 (cg-RX-API-DMAC7.html)
EP (2) EP3022223B1 (cg-RX-API-DMAC7.html)
JP (3) JP6628719B2 (cg-RX-API-DMAC7.html)
CN (2) CN110511960B (cg-RX-API-DMAC7.html)
AU (1) AU2014290288B2 (cg-RX-API-DMAC7.html)
CA (1) CA2918216C (cg-RX-API-DMAC7.html)
ES (2) ES2973064T3 (cg-RX-API-DMAC7.html)
WO (1) WO2015009606A1 (cg-RX-API-DMAC7.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3149031T (pt) 2014-05-29 2020-03-25 Us Health Receptores de células t anti-e7 do papilomavírus humano 16
US9422547B1 (en) 2015-06-09 2016-08-23 Gigagen, Inc. Recombinant fusion proteins and libraries from immune cell repertoires
EP3356396A1 (en) * 2015-10-01 2018-08-08 Ospedale San Raffaele S.r.l. Tcr and uses thereof
CA2998270A1 (en) 2015-10-01 2017-04-06 Ospedale San Raffaele S.R.L. Tcr and uses thereof
EP3156067A1 (en) * 2015-10-16 2017-04-19 Max-Delbrück-Centrum Für Molekulare Medizin High avidity hpv t-cell receptors
WO2017139199A1 (en) 2016-02-10 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible arginase
HRP20221375T1 (hr) * 2016-03-16 2023-01-06 Immatics Biotechnologies Gmbh Transfecirane t-stanice i t-stanični receptori za upotrebu u imunoterapiji protiv raka
DK3448882T3 (da) 2016-04-26 2022-02-21 Us Health Anti-kk-lc-1-t-cellereceptorer
DE102016115246C5 (de) * 2016-08-17 2018-12-20 Immatics Biotechnologies Gmbh Neue t-zellrezeptoren und deren verwendung in immuntherapie
ZA201900664B (en) 2016-08-17 2021-09-29 Paul Ehrlich Strasse 15 Tuebingen 72076 Germany T cell receptors and immune therapy using the same
KR20190062505A (ko) * 2016-10-03 2019-06-05 주노 쎄러퓨티크스 인코퍼레이티드 Hpv-특이적 결합 분자
IL299348B2 (en) 2017-06-28 2025-05-01 Regeneron Pharma Antigen-binding proteins against human papillomavirus and methods of using them
DE102017114737A1 (de) 2017-06-30 2019-01-03 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
CA3070468A1 (en) 2017-09-01 2019-03-07 Dana-Farber Cancer Institute, Inc. Immunogenic peptides specific to bcma and taci antigens for treatment of cancer
US11952408B2 (en) 2017-10-03 2024-04-09 Juno Therapeutics, Inc. HPV-specific binding molecules
US12227554B2 (en) * 2017-10-05 2025-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for selectively expanding cells expressing a TCR with a murine constant region
WO2019069125A1 (en) 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf CHIMERIC ANTIGEN RECEPTORS
JP7282760B2 (ja) 2017-10-18 2023-05-29 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法
ES3052818T3 (en) 2018-02-09 2026-01-14 Us Health Tethered interleukin-15 and interleukin-21
MA52003A (fr) 2018-03-12 2021-01-20 Sqz Biotechnologies Co Procédés de traitement de maladies associées au hpv
CN112585276A (zh) 2018-04-05 2021-03-30 朱诺治疗学股份有限公司 产生表达重组受体的细胞的方法和相关组合物
CN112585277A (zh) 2018-04-05 2021-03-30 朱诺治疗学股份有限公司 表达重组受体的t细胞、相关多核苷酸和方法
CN112566698A (zh) 2018-04-05 2021-03-26 朱诺治疗学股份有限公司 T细胞受体和表达该t细胞受体的工程化细胞
WO2019196088A1 (en) * 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of obtaining tumor-specific t cell receptors
CN112262212B (zh) 2018-04-24 2024-07-12 美国卫生和人力服务部 使用羟基柠檬酸和/或其盐产生t细胞群体的方法
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
BR112021002390A2 (pt) 2018-08-09 2021-05-11 Juno Therapeutics Inc processos para gerar células modificadas e suas composições
JP7289028B2 (ja) * 2018-09-05 2023-06-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 複数の主要組織適合遺伝子複合体分子に制限したｎｙ－ｅｓｏ－１－特異的ｔ細胞受容体の組成物
JP7504891B2 (ja) 2018-09-11 2024-06-24 ジュノー セラピューティクス インコーポレイテッド 操作された細胞組成物のマススペクトロメトリー分析のための方法
CN113727998A (zh) 2018-11-30 2021-11-30 高山免疫科学股份有限公司 Cd86变体免疫调节蛋白及其用途
EP3941938A1 (en) 2019-03-06 2022-01-26 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
WO2020191365A1 (en) 2019-03-21 2020-09-24 Gigamune, Inc. Engineered cells expressing anti-viral t cell receptors and methods of use thereof
CN113811329B (zh) 2019-04-19 2025-10-14 天科雅生物科技有限公司 抗pd-1抗体和其用途
CA3136737A1 (en) 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
US20220213167A1 (en) * 2019-05-03 2022-07-07 Gigamune, Inc. Engineered cells expressing anti-tumor t cell receptors and methods of use thereof
WO2021155518A1 (en) * 2020-02-05 2021-08-12 Tcrcure Biopharma Corp Anti-hpv t cell receptors and engineered cells
EP4125949A4 (en) * 2020-03-23 2024-05-22 The Council of the Queensland Institute of Medical Research COMPOSITIONS AND METHODS FOR TARGETING HPV-INFECTED CELLS
EP4171616A1 (en) 2020-06-26 2023-05-03 Juno Therapeutics GmbH Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
EP4243937A2 (en) 2020-11-13 2023-09-20 The United States of America, as represented by the Secretary, Department of Health and Human Services Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
CN114539385A (zh) * 2020-11-26 2022-05-27 香雪生命科学技术（广东）有限公司 一种识别hpv抗原的tcr
CN112480239B (zh) * 2020-12-02 2022-06-07 中国科学院微生物研究所 人乳头瘤病毒特异性t细胞受体及其抗肿瘤用途
CN114853878A (zh) * 2021-02-03 2022-08-05 香雪生命科学技术（广东）有限公司 一种针对hpv的高亲和力tcr
EP4370541A1 (en) 2021-07-14 2024-05-22 2seventy bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
WO2023036169A1 (en) * 2021-09-07 2023-03-16 Corregene Biotechnology Co., Ltd. Antigen binding proteins and uses thereof
WO2023050063A1 (zh) * 2021-09-28 2023-04-06 溧阳瑅赛生物医药有限公司 一种识别hla-a*02:01/e629-38的tcr及其应用
US20250243260A1 (en) 2022-03-07 2025-07-31 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies and related methods and uses
WO2023196884A1 (en) 2022-04-06 2023-10-12 Juno Therapeutics, Inc. Detection assay for human papillomavirus (hpv) type 16 (hpv-16)
AU2023248532A1 (en) 2022-04-08 2024-11-21 Regeneron Pharmaceuticals, Inc. Multipartite receptor and signaling complexes
CN115286690B (zh) * 2022-05-10 2023-06-20 广州医科大学 抗原短肽用于筛选治疗与hpv相关的疾病的药物中的用途及其筛选的tcr
AU2025212850A1 (en) 2024-01-26 2026-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1
CN118108854B (zh) * 2024-03-26 2024-07-19 广西福莱明生物制药有限公司 一种含有双特异性抗体的抗病毒组合物及其应用
WO2025250587A1 (en) 2024-05-29 2025-12-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Drug-regulatable, inducible cytokine expression

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1671733A (zh) * 2001-10-30 2005-09-21 科里克萨有限公司 用于wt1特异性免疫疗法的组合物和方法
WO2007131092A2 (en) * 2006-05-03 2007-11-15 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
CN103124740A (zh) * 2010-09-21 2013-05-29 美国卫生和人力服务部 抗-ssx-2 t细胞受体和相关材料及使用方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IN165717B (cg-RX-API-DMAC7.html) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
JPH10509948A (ja) * 1994-11-16 1998-09-29 バクスター インターナショナル インコーポレイテッド Ｔ細胞受容体ペプチドに対するヒト抗体およびそれらの調製方法
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
US8185966B2 (en) * 2005-07-25 2012-05-22 Trinity Future-IN PVT, Ltd. Electro-mechanical system for non-duplication of video files
CA2674445C (en) * 2007-01-12 2016-06-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Gp100-specific t cell receptors and related materials and methods of use
EP2468763B1 (en) 2007-05-31 2014-06-18 Academisch Ziekenhuis Leiden h.o.d.n. LUMC HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
GB0917090D0 (en) * 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1671733A (zh) * 2001-10-30 2005-09-21 科里克萨有限公司 用于wt1特异性免疫疗法的组合物和方法
WO2007131092A2 (en) * 2006-05-03 2007-11-15 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
CN103124740A (zh) * 2010-09-21 2013-05-29 美国卫生和人力服务部 抗-ssx-2 t细胞受体和相关材料及使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Promiscuous behavior of HPV16E6 specific T cell receptor beta chains hampers functional expression in TCR transgenic T cells, which can be restored in part by genetic modification;Scholten KB等;《Cellular Oncology》;20101231;第32卷(第1期);第43-56页 *

Also Published As

Publication number Publication date
US12187779B2 (en) 2025-01-07
US20230340066A1 (en) 2023-10-26
US20160152681A1 (en) 2016-06-02
US10913785B2 (en) 2021-02-09
EP3572423A1 (en) 2019-11-27
AU2014290288B2 (en) 2018-03-01
EP3022223B1 (en) 2019-06-19
US9822162B2 (en) 2017-11-21
JP7223822B2 (ja) 2023-02-16
JP2020054359A (ja) 2020-04-09
US20210130433A1 (en) 2021-05-06
US20190309043A1 (en) 2019-10-10
CA2918216A1 (en) 2015-01-22
US20180094041A1 (en) 2018-04-05
EP3572423B1 (en) 2023-12-06
ES2973064T3 (es) 2024-06-18
JP2016527230A (ja) 2016-09-08
JP6628719B2 (ja) 2020-01-15
CA2918216C (en) 2023-03-21
EP3022223A1 (en) 2016-05-25
CN110511960A (zh) 2019-11-29
CN105452288B (zh) 2019-08-13
WO2015009606A1 (en) 2015-01-22
US11697676B2 (en) 2023-07-11
US10329339B2 (en) 2019-06-25
JP6959970B2 (ja) 2021-11-05
ES2745472T3 (es) 2020-03-02
CN105452288A (zh) 2016-03-30
AU2014290288A1 (en) 2016-02-04
JP2022017292A (ja) 2022-01-25

Similar Documents

Publication Publication Date Title
CN110511960A (zh) 抗人乳头瘤病毒16 e6 t细胞受体
KR102533540B1 (ko) Pd-l1 키메라 항원 수용체-발현 nk 세포에 의한 pd-l1-양성 악성종양의 제거(elimination of pd-l1-positive malignancies by pd-l1 chimeric antigen receptor-expressing nk cells)
EP3383892B1 (en) Modified chimeric receptors and related compositions and methods
CN109276713A (zh) 嵌合的治疗性抗-cd37抗体hh1
AU2015346350C1 (en) Anti-thyroglobulin t cell receptors
KR20200004408A (ko) 뉴캐슬병 바이러스 및 이의 용도
KR20210019993A (ko) Τ 세포 수용체 및 이를 발현하는 조작된 세포
EP1441765A2 (en) Method for preparation of single chain antibodies
CN110559430B (zh) 一种抗淋巴瘤的car-t药物及其应用
KR20240000541A (ko) 키메라 항원 수용체(car)-t 세포
CN100548385C (zh) 一种布鲁氏杆菌核酸疫苗
CN113382741A (zh) Car t细胞方法和构建体
CN110628823B (zh) 一种cd30 car慢病毒表达载体及其制备方法和应用
HK40016948A (en) Anti-human papillomavirus 16 e6 t cell receptors
HK40016948B (en) Anti-human papillomavirus 16 e6 t cell receptors
AU2020394993A1 (en) Ny-eso-1-containing artificial adjuvant vector cell for use in treatment of cancer
CN108290940B (zh) Tcr及其用途
TW202227477A (zh) 識別p53中r273c或y220c突變的t細胞受體
JP2026515380A (ja) ｐ５３におけるＹ２２０ＣまたはＲ１７５Ｈ変異を標的とするＴ細胞受容体
KR20240032718A (ko) 키메라 항원 수용체(car)-t 세포
US20220193138A1 (en) Engineered natural killer cells redirected toward purinergic signaling, constructs thereof, and methods for using the same
KR20240032719A (ko) 키메라 항원 수용체(car)-t 세포
HK40068363A (en) Ny-eso-1-containing artificial adjuvant vector cell used for treating cancer
WO2024097448A1 (en) Recombinant poxviruses for cancer immunotherapy
CN117043180A (zh) 用于器官移植患者的免疫疗法的免疫抑制剂药物抗性装甲tcr t细胞

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40016948

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant